Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Presentation TCT 2017

Flash Debate: Bioresorbable Scaffolds Should Rarely be Used Outside of Carefully Controlled Research Studies!

Presenter: Sanjay Kaul, Tullio Palmerini, Robert A. Byrne

November 01, 2017

Presentation TCT 2017

Yukon and Coroflex ISAR Polymer-Free DES: Clinical Outcomes and Future Directions

Presenter: Mitchell W. Krucoff, Chaim S. Lotan, Robert A. Byrne

November 01, 2017

Presentation TCT 2017

Debate: ABSORB Is Likely Finished - The Limitation of the Technology Can Not Be Overcome

Presenter: Stephen G. Ellis, Takeshi Kimura, Robert A. Byrne

October 31, 2017

Presentation TCT 2017

DCB Preclinical Perspectives: Mechanisms and Experimental Safety and Efficacy of Older, Current, and Futuristic DCB

Presenter: Robert A. Byrne, Ran Kornowski, Juan F. Granada

October 30, 2017

$Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy$

Presentation TCT 2017

Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy

Presenter: Robert A. Byrne, Ran Kornowski, Ron Waksman

October 30, 2017

Presentation TCT 2017

Treatment of First-time In-Stent Restenosis State-of-the-Art Review: From Lesion Preparation and Imaging to Restenting to DCB

Presenter: Robert A. Byrne, Ran Kornowski, Fernando Alfonso

October 30, 2017

Presentation TCT 2017

Does DCB Technology Have an Important Role in Treatment of De Novo Coronary Artery Disease? If Not Today, Tomorrow?

Presenter: Robert A. Byrne, Ran Kornowski, Bernardo Cortese

October 30, 2017

Presentation TCT 2017

Drug-Coated Coronary Balloon Therapy: Current State-of-the-Art

Presenter: Robert A. Byrne, Ran Kornowski, Bruno Scheller

October 30, 2017

Presentation TCT 2017

Topic 4: At the Cusp of Diminishing Returns for CV Therapies - Personalized Approaches and New Frontiers

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Topic 3: Chronic Total Occlusion PCI - What Level of Evidence Is Required for Widespread Acceptance: Hard Endpoints vs QOL Measures

Presenter: Robert A. Byrne, Gregg W. Stone, J. Aaron Grantham

October 30, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Presenter: Robert A. Byrne, Gregg W. Stone, Aaron V. Kaplan

October 30, 2017

Presentation TCT 2017

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

Presenter: Dean J. Kereiakes, Spencer B. King III, Robert A. Byrne

October 30, 2017

Presentation TCT 2017

LAA Closure: Underused Therapy in Patients With High Bleeding Risk

Presenter: David Hildick-Smith, Lars Sondergaard, Robert A. Byrne

October 29, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

Presentation JIM 2017

Bioresorbable Scaffolds is a Real Need:CONTRA

Presenter: Robert A. Byrne

February 10, 2017

Presentation JIM 2017

The Synergy Stent: Optimal Healing in Complex Patients

Presenter: Robert A. Byrne

February 10, 2017

Advertisement

Flash Debate: Bioresorbable Scaffolds Should Rarely be Used Outside of Carefully Controlled Research Studies!

Yukon and Coroflex ISAR Polymer-Free DES: Clinical Outcomes and Future Directions

Debate: ABSORB Is Likely Finished - The Limitation of the Technology Can Not Be Overcome

DCB Preclinical Perspectives: Mechanisms and Experimental Safety and Efficacy of Older, Current, and Futuristic DCB

Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy

Treatment of First-time In-Stent Restenosis State-of-the-Art Review: From Lesion Preparation and Imaging to Restenting to DCB

Does DCB Technology Have an Important Role in Treatment of De Novo Coronary Artery Disease? If Not Today, Tomorrow?

Drug-Coated Coronary Balloon Therapy: Current State-of-the-Art

Topic 4: At the Cusp of Diminishing Returns for CV Therapies - Personalized Approaches and New Frontiers

Topic 3: Chronic Total Occlusion PCI - What Level of Evidence Is Required for Widespread Acceptance: Hard Endpoints vs QOL Measures

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

LAA Closure: Underused Therapy in Patients With High Bleeding Risk

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Bioresorbable Scaffolds is a Real Need:CONTRA

The Synergy Stent: Optimal Healing in Complex Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content